(Q46844955)

25 December 2017

title

Long-acting FGF21 has enhanced efficacy in diet-induced obese mice and in obese rhesus monkeys (English)

1 reference

25 December 2017

https://api.crossref.org/works/10.1210/EN.2012-1211

Long-Acting FGF21 Has Enhanced Efficacy in Diet-Induced Obese Mice and in Obese Rhesus Monkeys (English)

1 reference

6 January 2025

0 references

Renee Komorowski

2

1 reference

25 December 2017

Ping Chen

3

1 reference

25 December 2017

Shanaka Stanislaus

4

1 reference

25 December 2017

Katherine Winters

5

1 reference

25 December 2017

Todd Hager

6

1 reference

25 December 2017

Lei Zhou

7

1 reference

25 December 2017

Russell Wada

8

1 reference

25 December 2017

Randy Hecht

9

1 reference

25 December 2017

Jing Xu

10

1 reference

25 December 2017

Murielle M. Véniant

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A22798348

6 January 2025

language of work or name

English

0 references

publication date

13 July 2012

1 reference

25 December 2017

published in

Endocrinology

1 reference

25 December 2017

volume

153

1 reference

25 December 2017

issue

9

1 reference

25 December 2017

page(s)

4192-4203

1 reference

25 December 2017

The continuing increase of diabetes in the US

cites work

https://api.crossref.org/works/10.1210/EN.2012-1211

1

1 reference

6 January 2025

Epidemiology of diabetes

https://api.crossref.org/works/10.1210/EN.2012-1211

2

1 reference

Diabetes in America: epidemiology and scope of the problem

6 January 2025

https://api.crossref.org/works/10.1210/EN.2012-1211

3

1 reference

Pathogenesis of type 2 diabetes mellitus

6 January 2025

https://api.crossref.org/works/10.1210/EN.2012-1211

4

1 reference

Obesity and insulin resistance in humans: a dose-response study.

6 January 2025

https://api.crossref.org/works/10.1210/EN.2012-1211

5

1 reference

Lipids, diabetes, and coronary heart disease: insights from the Framingham Study.

6 January 2025

https://api.crossref.org/works/10.1210/EN.2012-1211

6

1 reference

Hypertension and type 2 diabetes comorbidity in adults in the United States: risk of overall and regional adiposity

6 January 2025

https://api.crossref.org/works/10.1210/EN.2012-1211

7

1 reference

Effects of intensive glucose lowering in type 2 diabetes

6 January 2025

https://api.crossref.org/works/10.1210/EN.2012-1211

8

1 reference

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

6 January 2025

https://api.crossref.org/works/10.1210/EN.2012-1211

9

1 reference

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

6 January 2025

https://api.crossref.org/works/10.1210/EN.2012-1211

10

1 reference

Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration

6 January 2025

https://api.crossref.org/works/10.1210/EN.2012-1211

11

1 reference

Insulin-associated weight gain in diabetes--causes, effects and coping strategies

6 January 2025

https://api.crossref.org/works/10.1210/EN.2012-1211

12

1 reference

Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes

6 January 2025

https://api.crossref.org/works/10.1210/EN.2012-1211

13

1 reference

Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes

6 January 2025

https://api.crossref.org/works/10.1210/EN.2012-1211

14

1 reference

Challenges and strategies for moving patients to injectable medications

6 January 2025

https://api.crossref.org/works/10.1210/EN.2012-1211

15

1 reference

FGF-21 as a novel metabolic regulator

6 January 2025

https://api.crossref.org/works/10.1210/EN.2012-1211

16

1 reference

The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21.

6 January 2025

https://api.crossref.org/works/10.1210/EN.2012-1211

17

1 reference

Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice

6 January 2025

https://api.crossref.org/works/10.1210/EN.2012-1211

18

1 reference

Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis

6 January 2025

https://api.crossref.org/works/10.1210/EN.2012-1211

19

1 reference

Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states

6 January 2025

https://api.crossref.org/works/10.1210/EN.2012-1211

20

1 reference

Fibroblast growth factor 21 regulates lipolysis in white adipose tissue but is not required for ketogenesis and triglyceride clearance in liver.

6 January 2025

https://api.crossref.org/works/10.1210/EN.2012-1211

21

1 reference

Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projections

6 January 2025

https://api.crossref.org/works/10.1210/EN.2012-1211

22

1 reference

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

6 January 2025

https://api.crossref.org/works/10.1210/EN.2012-1211

23

1 reference

Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability

6 January 2025

https://api.crossref.org/works/10.1210/EN.2012-1211

24

1 reference

Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models--association with liver and adipose tissue effects

6 January 2025

https://api.crossref.org/works/10.1210/EN.2012-1211

25

1 reference

Thyroid hormone regulates hepatic expression of fibroblast growth factor 21 in a PPARalpha-dependent manner

6 January 2025

https://api.crossref.org/works/10.1210/EN.2012-1211

26

1 reference

The link between fibroblast growth factor 21 and sterol regulatory element binding protein 1c during lipogenesis in hepatocytes

6 January 2025

https://api.crossref.org/works/10.1210/EN.2012-1211

27

1 reference

Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21

6 January 2025

https://api.crossref.org/works/10.1210/EN.2012-1211

28

1 reference

The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man.

6 January 2025

https://api.crossref.org/works/10.1210/EN.2012-1211

29

1 reference

Lack of Overt FGF21 Resistance in Two Mouse Models of Obesity and Insulin Resistance

6 January 2025

https://api.crossref.org/works/10.1210/EN.2012-1211

30

1 reference

6 January 2025

Identifiers

DOI

10.1210/EN.2012-1211

1 reference

25 December 2017

1 reference

25 December 2017